GABA Therapeutics is developing GRX-917, its lead drug candidate, for generalized anxiety disorder and other therapeutic indications. GRX-917 induces the production of endogenous brain neurosteroids which could benefit the lives of patients with life-altering neuropsychiatric, neurologic and pain disorders.
Many of these conditions represent some of the largest unmet medical needs in the United States and worldwide, including anxiety, anxious depression, postpartum depression, social anxiety disorder, panic disorder, pain and epilepsy.
